Literature DB >> 35022563

The effects of visual-field loss from panretinal photocoagulation of proliferative diabetic retinopathy on performance in a driving simulator.

Tomas Bro1, Jan Andersson2.   

Abstract

BACKGROUND: The purpose of this study was to compare driving-simulator performance of participants with visual-field loss (VFL) from panretinal photocoagulation (PRP) of proliferative diabetic retinopathy (PDR) with a normally sighted control group. Furthermore, we investigated the effects of VFL of different extent on driving.
METHODS: Data on performance and safety from a traffic-simulator test for 27 participants with VFL from PRP of PDR were retrospectively compared with data from 83 individuals without visual deficits in a cross-sectional study. Individuals with diabetes that regained their driving licences after a successful simulator test were then followed in a national accident database.
RESULTS: Diabetes participants passed the test in 56% of the cases. Compared with the control group, diabetes participants had more risky "failed to give way" events and longer reaction times. Failed diabetes participants had lower mean sensitivity in the superior visual field than those who passed. None of the participants with a regained licence were involved in a motor vehicle accident during the 3-6-year follow-up after the simulator test.
CONCLUSIONS: Diabetes participants had worse performance and safety than the controls. However, even individuals with VFL from PRP might drive safely, which highlights the need for individual assessments in licencing issues.
© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.

Entities:  

Year:  2022        PMID: 35022563     DOI: 10.1038/s41433-021-01832-3

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  1 in total

1.  Self-Perception and the Relation to Actual Driving Abilities for Individuals With Visual Field Loss.

Authors:  Jan Andersson; Tomas Bro; Timo Lajunen
Journal:  Front Hum Neurosci       Date:  2022-03-17       Impact factor: 3.169

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.